Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:1203 (19 November), doi:10.1136/bmj.331.7526.1203-b
| The first 150 words of the full text of this article appear below. |
EDITORExperts question the wisdom of stockpiling oseltamivir (Tamiflu).1 A question was asked about data supporting an improvement in mortality with the drug.
Two datasets were presented at the second European Influenza Conference in Malta (www.eswi.org) in September. A large retrospective cohort study of patients with influenza-like illness (n = 176 001) taken from a US health database showed that oseltamivir (75 mg twice daily, n = 39 202) significantly reduced the risks of pneumonia by 32% (P < 0.001) and of death by 91% (P < 0.05) (Nordstrom et al). In Canadian patients with laboratory-confirmed influenza (A or B) requiring hospital admission (< 15- > 64 years; n = 359), oseltamivir reduced the risk of death by 68% (McGeer et al). Treatment with oseltamivir therefore statistically and meaningfully reduces the risk of death in patients of all ages and from all walks of life, infected with
James R Smith, international medical leader
F Hoffman-La Roche, CH-4070 Basel, Switzerland james.smith.js1@roche.com
Regina Dutkowski, clinical science leader
Hoffmann-La Roche, Nutley, NJ 07110, USA
Read all Rapid Responses